BioAge Labs (NASDAQ:BIOA) Rating Increased to Hold at Wall Street Zen

BioAge Labs (NASDAQ:BIOA) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Sunday.

Several other research firms also recently commented on BIOA. Citigroup upped their price target on shares of BioAge Labs from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a research report on Thursday, October 30th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $15.00.

BioAge Labs Trading Down 6.3%

BioAge Labs stock opened at $20.16 on Friday. The company has a market capitalization of $722.84 million, a price-to-earnings ratio of -13.26 and a beta of 1.38. BioAge Labs has a 12 month low of $2.88 and a 12 month high of $24.00. The stock’s 50 day moving average is $12.22 and its 200-day moving average is $7.66.

BioAge Labs (NASDAQ:BIOA) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.11. The firm had revenue of $2.05 million during the quarter.

Insider Activity at BioAge Labs

In other news, CFO Dov A. Md Goldstein sold 27,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $19.70, for a total value of $531,900.00. Following the sale, the chief financial officer directly owned 22,408 shares in the company, valued at approximately $441,437.60. This trade represents a 54.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Paul D. Rubin sold 18,000 shares of BioAge Labs stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $12.00, for a total transaction of $216,000.00. The SEC filing for this sale provides additional information. Insiders have sold 347,004 shares of company stock valued at $5,673,859 over the last ninety days. 20.82% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On BioAge Labs

Large investors have recently modified their holdings of the business. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of BioAge Labs in the 2nd quarter valued at about $27,000. Russell Investments Group Ltd. acquired a new position in shares of BioAge Labs in the third quarter worth approximately $27,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in BioAge Labs by 85.6% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock valued at $54,000 after acquiring an additional 5,976 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new stake in BioAge Labs during the 2nd quarter valued at approximately $57,000. Finally, Intech Investment Management LLC bought a new position in BioAge Labs during the 2nd quarter worth approximately $60,000.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.